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8-week PPI therapy in patients with mild erosive esophagitis (Los Angeles Grade A/B erosive
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prazole 40mg daily for 8weeks. The characteristics of eligible patients including clinical factors,
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Incomplete therapy response in erosive esophagitis 19were checked on enrollment. Patients were asked to record symptoms with diary cards during
the follow-up period. The major outcome measurement was incomplete symptom response.
Results: In total, 232 patients (male/female, 126/106) participated in this study. Following 8-
week esomeprazole therapy, 50 (21.6%) of the patients had incomplete symptom response. Uni-
variate analysis showed that sex, alcohol consumption, underlying diseases, regurgitation of
food, chest pain, globus, and insomnia were associated with incomplete symptom response
(pZ 0.049, pZ 0.006, pZ 0.023, pZ 0.010, pZ 0.013, pZ 0.009, and p < 0.001, respec-
tively). Multivariate analysis with stepwise logistic regression revealed that only globus [95% con-
fidence interval (CI): 1.185e4.897; pZ 0.015] and insomnia (95% CI: 1.289e3.018; pZ 0.002)
were independent risk factors for incomplete symptom response with odds ratio (OR)Z 2.4
and ORZ 2.0, respectively.
Conclusion: Of the patients with Los Angeles Grade A/B erosive esophagitis, 21.6% failed to have
complete symptom resolution following 8-week PPI therapy. Globus and insomnia are two inde-
pendent factors predicting incomplete symptom response in patients with mild erosive esopha-
gitis.
Copyright ª 2014, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society
of Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.Introduction
Gastroesophageal reflux disease (GERD) is a common acid-
peptic disorder characterized by recurrent troublesome
reflux symptoms and esophageal injury. It is the strongest
known risk factor for esophageal adenocarcinoma [1,2].
Many studies indicated that the prevalence of GERD is
markedly higher in Western populations than in Asian pop-
ulations [3e6]. However, the prevalence of GERD has
increased in Asia in recent decades [7,8]. Our studies
demonstrated that the recent prevalence of GERD in the
general population and erosive esophagitis in patients un-
dergoing health check-ups in Taiwan were 25% and 17%,
respectively [7,8]. The reasons for the increasing preva-
lence of erosive esophagitis in Asia remain unclear, but are
probably related to the changes in lifestyles, westerniza-
tion of diet, lack of exercise, aging of population, and a
decrease in Helicobacter pylori infection [9].
Currently, therapy for erosive esophagitis largely focuses
on the pharmacological reduction of gastric acid secretion.
Reducing the acidity of gastric juice ameliorates reflux
symptoms and allows esophagitis to heal [10e12]. None-
theless, incomplete symptom resolution to proton pump in-
hibitor (PPI) therapy is a common problem in the treatment
of GERD and affects a significant proportion of patients who
use a PPI once daily [13]. The putative mechanisms for poor
symptom response to PPIs include poor compliance,
improper timing of PPI consumption, reduced PPI bioavail-
ability, non-acid reflux, visceral hypersensitivity, delayed
gastric emptying, psychological comorbidity, and concomi-
tant functional bowel disorders [13,14]. Recently, Cheong
et al [15] showed that an abnormal Hill’s gastroesophageal
flap valve (GEFV) was a significant factor predicting poor
response of GERD to PPI treatment. However, whether other
factors including pretreatment symptom profiles, rapid PPI
metabolism, obesity, metabolic syndrome, and H. pylori
infection status play important roles in poor symptom
response in GERD patients is unclear.The aims of this study were (1) to examine the rate of
incomplete symptoms response following 8-week PPI ther-
apy in patients with mild erosive esophagitis (Los Angeles
Grade A/B) and (2) to determine the independent factors
predicting incomplete symptom response in patients with
mild erosive esophagitis.
Methods
Patients
This study was a multicenter trial. From January 2010 to July
2012, patients between theages of 15 years and80 yearswith
(1) clinical symptoms of acid regurgitation, heartburn, or
feeling of acidity in the stomach and (2) endoscopic exami-
nation showing Los Angeles Grade A or B erosive esophagitis
[16] were recruited for the study. Criteria for exclusion
included (1) coexistence of peptic ulcer or gastrointestinal
malignancies, (2) coexistence of serious concomitant illness
(for example, decompensated liver cirrhosis and uremia), (3)
previous gastric surgery, (4) allergy to esomeprazole
(Nexium, Astrazeneca, 21F, No. 207, Dunhua South Road,
Section 2, Taipei City), (5) symptom score of a validated
questionnaire (Chinese GERDQ)< 12 [17], (6) pregnancy, (7)
frequent (> 3 times/wk) use of hypnotics. Written informed
consent was obtained from each patient.
Study design
On enrollment, patients were requested to complete a
Chinese GERDQ [17]. In the scoring system, the GERD
symptoms included acid regurgitation, heartburn, and
feeling of acidity in the stomach. The severity and fre-
quency of symptoms were graded on a 5-point Likert scale
as follows: none (no symptoms/none in the past year); mild
(symptoms can be ignored/< once monthly); moderate
(awareness of symptoms but tolerated easily/  once
20 S.-S. Kao et al.monthly); severe (symptoms sufficient to interfere with
normal activities/  once weekly); and incapacitating
(incapacitating symptoms hindering daily activities or
requiring a day off work/  once daily). A cut-off score of 
12 achieved the highest accuracy for the diagnosis of
symptomatic GERD in the previous study [17]. We therefore
only recruited patients with scores of Chinese GERDQ  12.
The body mass index (BMI) of each patient was checked
on enrollment. Also, blood sampling for genotyping of
CYP2C19 (cytochrome P450 2C19) was carried out. Gastric
biopsy over the antrum and body for H. pylori examination
was performed during the initial endoscopy. The recruited
patients were treated with esomeprazole (Nexium, Astra-
zeneca, 21F, No. 207, Dunhua South Road, Section 2, Taipei
City) 40 mg daily for 8 weeks. During the study period, they
were asked to record symptoms with diary cards. The pa-
tients returned to the clinic for drug refills and handed in
symptom diary cards every 4 weeks. The major outcome
measurement was incomplete symptom response, which
was defined as experiencing reflux symptoms (acid regur-
gitation, heartburn, or feeling of acidity in the stomach)
sufficient to result in troublesome feelings in the patient
during the previous 7 days of treatment.
Demographic data of patients
A complete medical history and demographic data were ob-
tained for each patient, including age, sex, medical history,
history of smoking, alcohol, coffee and tea consumption, and
duration, frequency, and severity of reflux symptoms.
H. pylori examination
Two biopsy specimens were taken from the lesser curvature
sites of the antrum and the corpus, respectively. They were
fixed in 10% buffered formalin, embedded in paraffin, and
sectioned. The sections, 4-mm thick, were stained with a
hematoxylin and eosin stain and a modified Giemsa stain to
observe the presence of curved rod-shape bacteria on the
mucosal surface [18]. Biopsy specimens were assessed by a
histopathologist (H.H. Tseng), who was blinded to patient
status and the results of other laboratory tests.
Genotyping of CYP2C19
Blood sampling for genotyping of CYP2C19 was carried out
prior to endoscopy for the patients who provided informed
consent for the genetic study. The CYP2C19 genotype was
determined using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) analysis [19].
Genotypes were classified into three groups: homogeneous
extensive metabolizer (homEM, CYP2C19*1/CYP2C19*1);
heterogeneous extensive metabolizer (hetEM, CYP2C19*1/
CYP2C19*2 and CYP2C19*1/CYP2C19*3); and poor metabo-
lizer (PM, CYP2C19*2/CYP2C19*2, CYP2C19*2/CYP2C19*3,
and CYP2C19*3/CYP2C19*3).
Statistical analysis
To determine the independent factors affecting the treat-
ment response and clinical and genetic factors, the Chi-square test or Fisher’s exact test was employed to investi-
gate the relationships between the rate of incomplete
symptom response and clinical characteristics. The clinical
variables included the following: age (< 60 years or  60
years), sex, history of smoking, history of alcohol con-
sumption (< 80 g/d or  80 g/d), ingestion of coffee
(< 1 cup/d or  1 cup/d), ingestion of tea (< 1 cup/d or 
1 cup/d), coexistence of a systemic disease (yes or no),
insomnia (difficulty in falling asleep> 15minutes after going
to bed  1 d/wk), grade of erosive esophagitis, BMI, geno-
type of CYP2C19, andH. pylori status. All statistical analyses
were performed using the SPSS program (version 10.1; SPSS
Inc., Chicago, IL, USA). A p value < 0.05 was considered to
be statistically significant. The variables found to be sig-
nificant by univariate analysis were subsequently assessed
by a stepwise logistic regression method to identify inde-
pendent factors for incomplete symptom response.
Results
Patient characteristics and endoscopic
characteristics
In total, 232 patients [mean age  standard deviation (SD),
52.7  11.5 years; male/female, 126/106] participated in
this study. Table 1 shows the demographic data of these
participants. Among them, the frequencies of heartburn,
epigastric acidic discomfort, and acid regurgitation were
62.1%, 74.1%, and 88.8%, respectively. Fifty patients
(21.6%) had hiatal hernia, and 37 patients had an abnormal
Hill’s GEFV [Grade III: 26 (13.8%); Grade IV: 11 (5.8%)]. The
frequencies of homEMs, hetEMs, and PMs of CYP2C19 ge-
notypes in these patients were 35%, 53%, and 12%,
respectively. The prevalence of H. pylori infection was 24%.
Univariate analysis for incomplete symptom
response in patients with mild erosive esophagitis
Following 8-week esomeprazole therapy, 50 (21.6%) of the
erosive esophagitis patients had incomplete symptom
response. Table 2 shows the associations between incom-
plete symptom response and patient characteristics
(including clinical, genetic, and bacterial factors on
enrollment). The incidence of incomplete symptom
response was higher in females than in males (27.4% vs.
16.7%). Additionally, alcohol consumption, underlying dis-
eases, regurgitation of food, chest pain, globus (sensation
of a lump or foreign body in the throat), and insomnia were
significantly associated with incomplete symptom response
(p Z 0.006, p Z 0.023, p Z 0.010, p Z 0.013, p Z 0.009,
and p < 0.001, respectively). However, advanced age,
CYP2C19 genotype, smoking, coffee and tea consumption,
high BMI, and H. pylori infection were not significantly
associated with incomplete symptoms response.
Multivariate analysis for incomplete symptom
response in patients with mild erosive esophagitis
Table 3 shows the independent factors predicting incom-
plete symptom response. Multivariate analysis with
Table 1 Demographic data of patients with mild erosive
esophagitis.
Characteristics Patients with mild
erosive esophagitis
(n Z 232)
Clinical factors
Age (y; mean  SD) 52.7  11.5
Sex (male/female) 126/106
Smoking
() 196 (84.5)
(þ) 36 (15.5)
Alcohol consumption
() 180 (77.6)
(þ) 52 (22.4)
Ingestion of coffee
() 122 (52.6)
(þ) 110 (47.4)
Ingestion of tea
() 99 (42.7)
(þ) 133 (57.3)
Ingestion of spicy food
() 131 (56.5)
(þ) 101 (43.2)
Ingestion of sweet food
() 89 (38.4)
(þ) 143 (61.6)
Underlying diseases
() 139 (59.9)
(þ) 93 (40.1)
BMI
< 25 123 (53.0)
 25 109 (47.0)
Endoscopic findings
Erosive esophagitis
Grade A 170 (73.3)
Grade B 62 (26.7)
Hiatal hernia
() 182 (78.4)
(þ) 50 (21.6)
Hill’s GEFV
Grade I/II 152 (80.4)
Grade III/IV 37 (19.6)
H. pylori status
() 176 (75.9)
(þ) 56 (24.1)
Data are presented as n (%), unless otherwise indicated.
BMI Z body mass index; GEFV Z gastroesophageal flap valve;
H. pylori Z Helicobacter pylori; SD Z standard deviation.
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dence interval (CI): 1.185e4.897; p Z 0.015] and insomnia
(95% CI: 1.289e3.018; p Z 0.002) on enrollment were in-
dependent risk factors for incomplete symptom response
with odds ratio (OR) Z 2.4 and OR Z 2.0, respectively
(Table 3).
Discussion
Currently, limited information is available on predictors of
the response to PPI treatment in patients with erosiveesophagitis. In this study, we demonstrated that 21.6% of
the patients with Los Angeles Grade A/B erosive esophagitis
had incomplete symptom resolution to 8-week esomepra-
zole treatment. The incomplete symptom response rate
ranged from 28% to 59% in previous studies (Table 4). The
wide range of symptom response rate is probably due to
different study populations, types of PPI use, duration of
PPI therapy, and definition of poor symptom response. In
this study, globus and insomnia on enrollment were inde-
pendent risk factors predicting incomplete symptom
response in these patients. Other patient characteristics
including Hill’s GEFV, CYP2C19 genotype, and H. pylori
status were not significant independent factors related to
incomplete symptom response.
Globus is a persistent or intermittent nonpainful sensa-
tion of a lump or foreign body in the throat between meals
[20]. The etiology of globus is still unclear but appears to be
multifactorial including GERD, abnormalities of the upper
esophageal sphincter, visceral hypersensitivity and psychi-
atric disorders, and stress [21]. GERD has been suggested to
be a major cause of this symptom [22,23]. Two basic
mechanisms have been proposed to explain the association
between GERD and the globus sensation: (1) direct irrita-
tion and inflammation of the laryngopharynx by retrograde
flow of gastric contents; and (2) vasovagal reflex hyperto-
nicity of the upper esophageal sphincter triggered by
acidification of the distal esophagus [24e26]. In this study,
the frequency of globus in Los Angeles Grade A/B erosive
esophagitis patients was 49.6% (115/232). Multivariate
analysis revealed that globus before PPI therapy was an
independent factor predicting incomplete symptom
response in patients with mild esophagitis. Currently, the
reasons for poor symptom response in erosive esophagitis
patients with globus remain unclear. Nonetheless, erosive
esophagitis patients with globus might have more acidic
refluxate reaching upper esophagus and larynx than those
without globus. Double-dose PPI has been recommended
for the treatment of extraesophageal symptoms of GERD
[27,28]. Therefore, the single-dose PPI used in this study
might be insufficient to control symptoms in some of our
patients with globus. It is also important to note that globus
is common in conjunction with reflux symptoms, and a
strong relationship between GERD and globus has not been
well established [29]. Due to its multi-pathogenesis nature,
globus does not appear to respond well to antireflux
therapy.
In this study, insomnia is another independent factor
predicting incomplete symptom response. The symptom
affected 13.8% (32/232) of the erosive esophagitis patients
in the current study. Previous studies showed that gastro-
esophageal reflux is a major cause of disrupted sleep due to
awakenings from heartburn, dyspepsia, acid brash, cough-
ing, or choking [30]. However, it is noteworthy that
insomnia is not a symptom; instead, this is a disorder. It can
be induced by excessive nocturnal reflux or nonreflux fac-
tors such as stress and psychological disorders. Therefore,
the association between insomnia and incomplete symptom
response in this study is possibly due to excessive nocturnal
reflux or psychological factors in patients with mild erosive
esophagitis [31,32]. The exact mechanism underlying the
associations between insomnia and incomplete symptom
response merits further studies.
Table 2 Univariate analysis for incomplete symptom
response in patients with mild erosive esophagitis.
Characteristics No. of
patients
Incomplete
symptoms
response
p
Clinical factors
Sex
Female 106 29 (27.4) 0.049*
Male 126 21 (16.7)
Age
< 60 y 165 33 (20.0) 0.367
 60 y 67 17 (25.4)
Smoking
() 196 44 (22.4) 0.438
(þ) 36 6 (16.7)
Alcohol consumption
() 180 46 (25.6) 0.006*
(þ) 52 4 (7.7)
Ingestion of coffee
() 122 28 (23.0) 0.585
(þ) 110 22 (20.0)
Ingestion of tea
() 99 27 (27.3) 0.067
(þ) 133 23 (17.3)
Ingestion of spicy food
() 131 32 (24.4) 0.225
(þ) 101 18 (17.8)
Ingestion of sweet food
() 89 20 (22.5) 0.788
(þ) 143 30 (21.0)
Underlying diseases
() 139 23 (16.5) 0.023*
(þ) 93 27 (29.0)
BMI
< 25 123 31 (25.2) 0.151
 25 109 19 (17.4)
Symptom profiles
Acid regurgitation
() 26 3 (11.5) 0.188
(þ) 206 47 (22.8)
Heartburn
() 88 16 (18.2) 0.329
(þ) 144 34 (23.6)
Epigastric acidity
() 60 11 (18.3) 0.481
(þ) 172 39 (22.7)
Epigastric fullness
() 93 22 (22.7) 0.524
(þ) 139 28 (20.1)
Regurgitation of food
() 143 23 (16.1) 0.010*
(þ) 89 27 (30.3)
Nausea
() 166 33 (19.9) 0.326
(þ) 66 17 (25.8)
Vomiting
() 206 46 (22.3) 0.417
(þ) 26 4 (15.4)
Belching
() 111 25 (22.5) 0.731
(þ) 121 25 (20.7)
Table 2 (continued )
Characteristics No. of
patients
Incomplete
symptoms
response
p
Chest pain
() 142 23 (16.2) 0.013*
(þ) 90 27 (30.0)
Dysphagia
() 194 38 (19.6) 0.100
(þ) 38 12 (31.6)
Globus
() 117 17 (14.5) 0.009*
(þ) 115 33 (28.7)
Sore throat
() 194 42 (21.6) 0.935
(þ) 38 8 (21.1)
Hoarseness
() 169 36 (21.3) 0.879
(þ) 63 14 (22.2)
Cough
() 178 36 (20.2) 0.372
(þ) 54 14 (25.9)
Insomnia
() 200 35 (17.5) < 0.001*
(þ) 32 15 (46.9)
Laboratory tests
CYP2C19 genotype
HomEM 62 10 (16.1) 0.199
HetEM 95 19 (20.0)
PM 21 4 (19.0)
Endoscopic findings
Hiatal hernia
() 188 45 (23.9) 0.068
(þ) 44 5 (11.4)
Hill’s GEFV
Grade I/II 152 29 (19.1) 0.727
Grade III/IV 37 8 (21.6)
Erosive esophagitis
LA Grade A 170 40 (23.5) 0.225
LA Grade B 62 10 (16.1)
H. pylori infection
() 176 40 (22.7) 0.677
(þ) 56 11 (19.6)
Data are presented as n (%), unless otherwise indicated.
*p < 0.05.
BMI Z body mass index; CYP2C19 Z cytochrome P450 2C19;
GEFV Z gastroesophageal flap valve; hetEM Z heterogeneous
extensive metabolizer; homEM Z homogeneous extensive
metabolizer; H. pylori Z Helicobacter pylori; LA Z Los
Angeles; PM Z poor metabolizer.
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and pantoprazole, are metabolized by CYP2C19 in the liver.
There are genetic differences in the activity of this enzyme
[33]. These CYP2C19 genotypic differences in pharmacoki-
netics and pharmacodynamics of PPIs influence the healing
of erosive esophagitis [34] and eradication rates of H. pylori
infection by PPI-based regimens [35]. In this study, the
incomplete response rate in homEMs, hetEMs, and PMs was
Table 3 Multivariate analysis for incomplete symptom
response in patients with mild erosive esophagitis.
Clinical
factor
Coefficient Standard
error
OR (95% CI) p
Globus 0.879 0.362 2.409 (1.185e4.897) 0.015
Insomnia 0.679 0.217 1.973 (1.289e3.018) 0.002
CI Z confidence interval; OR Z odds ratio.
Table 4 The frequencies of poor symptom response in patients with gastroesophageal reflux disease.
Authors Patients
(no. of cases)
PPI use Duration of
PPI use (wk)
Definition of poor
response
Frequency of
poor symptom
response (%)
Cheong et al [15] EE (n Z 119) Pantoprazole,
(40 mg daily)
8  50% reduction in
symptom scores
28
Zerbib et al [36] NERD þ EE
(n Z 100)
Various kinds of PPI
(standard or double-dose
PPI daily)
 4  2 d of mild symptoms per
wk under PPI treatment
57
Carlsson et al [37] NERD þ EE
(n Z 538)
Omeprazole (20 mg daily) 4 Completely symptom free
during Wk 4
59
Bate et al [38] NERD þ EE
(n Z 112)
Omeprazole (20 mg daily) 4 More than mild symptoms in
the previous 7 d
34
Current study EE (n Z 232) Esomeprazole (40 mg daily) 8 Reflux symptoms sufficient to
lead to troublesome feelings
during the previous 7 d
22
EE Z erosive esophagitis; NERD Z nonerosive reflux disease; PPI Z proton pump inhibitor.
Incomplete therapy response in erosive esophagitis 2316%, 20%, and 19%, respectively. There were no significant
differences in response rates among the three groups of
patients.
Although Cheong et al [15] showed that abnormal GEFV
was a significantly independent factor predicting poor
response to pantoprazole treatment in GERD patients, the
current study did not find differences in treatment
response between patients with different grades of GEFV.
The reason for the conflicting results is unclear and merits
further investigation.
This study has several limitations. First, only the pa-
tients with mild erosive esophagitis were recruited for this
study. Whether or not the identified risk factors for
incomplete symptom response to PPI therapy can be
applied to patients with nonerosive reflux disease (NERD) or
severe erosive esophagitis remains unanswered. Second,
the study was carried out in a single country. The data will
need to be confirmed in regions with different ethnic
populations. Third, the study did not use a questionnaire to
assess the psychological status of the enrolled patients.
Whether psychological factors (such as depression and
anxiety) could be the main causes for the refractory
symptoms as well as insomnia and globus is still unclear.
Fourth, insomnia in this study was defined only by subjec-
tive evaluation with the questionnaire; therefore, it may
not reflect an actual diagnosis of insomnia. However, this is
the first work that simultaneously evaluates multiple clin-
ical, endoscopic, and genetic parameters by multivariate
analysis to identify the risk factors of incomplete treatmentresponse in PPI therapy for patients with mild erosive
esophagitis.
In conclusion, 21.6% of the patients with Los Angeles
Grade A/B erosive esophagitis fail to complete symptom
resolution following 8-week PPI therapy. Globus and
insomnia are two independent factors for incomplete
symptom response in patients with mild erosive
esophagitis.Conflicts of interest
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